Soliris

Indicated For

gMG, PNH, aHUS

About This Medication

# Alexion OneSource Patient Guide: How to Get Soliris at Low or No Cost ## About This Program Alexion OneSource is a complimentary, personalized patient support program offered by Alexion Pharmaceuticals designed to help patients access Soliris (eculizumab) and manage their treatment journey. The program provides financial assistance, insurance navigation support, educational resources, and community connections for eligible patients. ## What is Soliris? Soliris is an FDA-approved medication used to treat specific rare conditions including generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD), and other complement-mediated disorders. Your healthcare provider will determine if Soliris is appropriate for your condition. ## Who Qualifies for Alexion OneSource? To be eligible for the Alexion OneSource program, you must meet the following criteria: - Have a valid prescription for Soliris from a licensed healthcare provider for an FDA-approved indication - Be a US resident - Have commercial insurance coverage, be uninsured, or be underinsured - Be willing to enroll in the OneSource program and provide necessary health information The program is designed to support patients regardless of insurance status, though specific eligibility for free medication or copay assistance depends on your individual circumstances. ## Insurance Requirements and Financial Assistance Alexion OneSource works with patients who have various insurance situations: | Insurance Status | Program Support | |---|---| | Commercial Insurance | Copay assistance available through Alexion OneSource CoPay Program | | Uninsured | Medication may be available at no cost if eligible | | Underinsured | Financial assistance and copay support available | The program does not require you to have prescription insurance coverage. If you lack insurance or have limited coverage, you may still qualify for assistance. ## Step-by-Step Application Process ### Step 1: Gather Required Documents Before starting your application, collect the following: - Front and back copies of your medical insurance card (if applicable) - Front and back copies of your pharmacy coverage card (if applicable) - Your prescription for Soliris from your healthcare provider - Proof of US residency ### Step 2: Complete Your Enrollment Form You have two options for completing your enrollment: **Option A: Online Enrollment** Visit AlexionOneSource.com and select "I am a patient or legal representative." Follow the guided online process to complete your enrollment form. **Option B: Download and Mail/Fax** Download the patient enrollment form from AlexionOneSource.com. Complete all required sections (marked in red) and sign the Authorization to Share Health Information section. ### Step 3: Submit Your Application Once your form is complete and signed, submit it along with copies of your insurance and pharmacy cards using one of these methods: - **Email:** OneSource@Alexion.com - **Fax:** 1-800-420-5150 - **Phone:** Call 1-888-765-4747 to discuss your application or ask questions ### Step 4: Verification and Approval Alexion OneSource will review your application and verify your eligibility. They will contact you to confirm receipt and provide updates on your enrollment status. ### Step 5: Receive Your Medication Once enrolled and approved, Soliris will be shipped to your home or your healthcare provider's office, depending on your treatment plan and site of care. ## Important Pre-Treatment Requirement Before receiving your first dose of Soliris, you must complete or update your meningococcal vaccine(s) at least 2 weeks before treatment begins. This is a critical safety requirement. Discuss vaccination timing with your healthcare provider. ## Timeline and Delivery While specific processing times are not publicly detailed, Alexion OneSource works to process applications efficiently once all required documentation is received. Medication is typically shipped to either your home or your healthcare provider's office, depending on your treatment setting. For ongoing therapy, reauthorizations may be required. Your OneSource support team will guide you through this process. ## What Happens If Your Application is Denied If your application is denied, you have options: - Contact OneSource at 1-888-765-4747 to understand the reason for denial - Ask about appeals or reapplication processes - Discuss alternative financial assistance programs with your healthcare provider - Work with your healthcare provider's office to explore other coverage options ## Ongoing Support and Reauthorization Enrollment in Alexion OneSource is not a one-time process. The program provides: - Ongoing personalized support throughout your treatment - Help navigating insurance and reauthorizations - Assistance if you travel and need to continue your care - Educational resources about your condition and treatment - Community connections with other patients Your OneSource support team will contact you about reauthorizations as needed to ensure continuous access to your medication. ## Language Support If English is not your preferred language, Alexion OneSource provides interpreter services at no cost. Simply call 1-888-765-4747 and request language support. ## Contact Information - **Phone:** 1-888-765-4747 (available for questions before enrollment) - **Email:** OneSource@Alexion.com - **Fax:** 1-800-420-5150 - **Website:** AlexionOneSource.com ## Important Disclaimer This guide provides general information about the Alexion OneSource program. Program details, eligibility requirements, and available assistance may change. For the most current and complete information, visit AlexionOneSource.com or contact the program directly. This information is not medical advice. Always consult with your healthcare provider about your treatment options and eligibility for assistance programs. Your healthcare provider's office can also help you navigate the enrollment process and answer specific questions about your individual situation.

Program information last verified: March 30, 2026